ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1428

Discovery and Characterization of JNJ-61178104, a Bispecific Antibody Against Human Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL)-17A

Fang Shen1, Jennifer F. Nemeth2, Brian Jones1, Ann Cai1, Shannon Hitchcock3, Thai Dinh2, Ravi Malaviya1 and Tatiana Ort1, 1Immunology, Janssen R&D, Spring House, PA, 2Janssen Biotech, Janssen R&D, Spring House, PA, 3Immunology, Janssen R&D, Springhouse, PA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Antibodies, interleukins (IL), Psoriatic arthritis, rheumatoid arthritis (RA) and tumor necrosis factor (TNF)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Tumor necrosis factor alpha (TNFa) and interleukin (IL)-17A are pleiotropic cytokines implicated in the pathogenesis of several autoimmune diseases including Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA). It has been suggested that TNFa and IL-17A drive independent actions on cellular inflammatory responses resulting in significantly increased proinflammatory mediator output. Targeting both TNFa and IL-17A has been proposed to have potential to achieve better and long lasting efficacy with a favorable safety profile in RA and PsA.

Methods:

JNJ-61178104 is a novel human anti-TNF-a and anti-IL‑17A bispecific antibody. The affinities of JNJ-61178104 binding to TNFa and IL-17A were assessed by surface plasmon resonance. The functional activity of JNJ 61178104 was evaluated in several preclinical cell based assays to characterize neutralization in the conditions where only one or both cytokines were present. Given the bispecific nature of JNJ‑61178104, the ability to neutralize both TNFa and IL-17A simultaneously was assessed in a co-culture model. To evaluate pharmacodynamics (PD) activity of JNJ-61178104 in vivo, Balb/c mice were treated with intranasal instillation of TNFa and IL-17A to induced acute lung inflammation. Proinflammatory cytokine production was assessed by ELISA and cellular influx was enumerated in lung lavage.

Results:

JNJ-61178104 binds to both TNFa (KD= 1.88~2.11 x 10-11 M) and IL-17A (KD= 2.20~4.53 x 10-11 M) with high affinity and inhibits binding of human TNFa to its receptors (IC50 = 0.92~1.96 nM) or human IL-17A to IL-17RA receptor (IC50 = 1.18 nM). JNJ-61178104 also potently neutralizes soluble TNFa (IC50 = 0.22~1.33 nM), transmembrane TNFa (IC50 = 0.74 nM), IL-17A- and IL 17A/F heterodimer (IC50 = 0.32~3.06 nM) -mediated responses in multiple cell based assays.

In a co-culture system consisting of human synovial-like-fibroblast cells isolated from an RA donor and activated human Th1/Th17 cells, either parental anti-TNFa antibody or parental anti-IL-17A antibody only partially inhibit cytokines production, while JNJ-61178104 inhibited IL-6 and GROa production in a dose dependent manner similarly to the combination of parental antibodies.

In the acute pharmacodynamics model, while the parental anti-TNFa antibody or parental anti-IL-17A antibody dosed at 10 mg/kg partially attenuated cell accumulation in the lung, treatment with the JNJ 61178104 at 1 mg/kg, 3 mg/kg, and 10 mg/kg resulted in a significant, dose dependent inhibition of cell influx, with a near complete ablation of total cells/neutrophils in the lung with the highest dose of 10 mg/kg.

Conclusion:

Overall, JNJ-61178104 demonstrated potent functional neutralization of both TNFa and IL-17A driven inflammatory responses in vitro and in vivo preclinical models. Favorable pharmacological profile of JNJ-61178104, i.e., along with significant clinical experience with both TNFα and IL-17A pathways in RA and PsA subjects support the clinical investigation of JNJ-61178104 in autoimmune and inflammatory disease.


Disclosure: F. Shen, Johnson & Johnson, 3,Johnson & Johnson, 1; J. F. Nemeth, Johnson & Johnson, 3,Johnson & Johnson, 1; B. Jones, Johnson & Johnson, 3; A. Cai, Johnson & Johnson, 3; S. Hitchcock, Johnson & Johnson, 3; T. Dinh, Johnson & Johnson, 3; R. Malaviya, Johnson & Johnson, 3,Johnson & Johnson, 1; T. Ort, Johnson & Johnson, 3,Johnson & Johnson, 1.

To cite this abstract in AMA style:

Shen F, F. Nemeth J, Jones B, Cai A, Hitchcock S, Dinh T, Malaviya R, Ort T. Discovery and Characterization of JNJ-61178104, a Bispecific Antibody Against Human Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL)-17A [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/discovery-and-characterization-of-jnj-61178104-a-bispecific-antibody-against-human-tumor-necrosis-factor-tnf-alpha-and-interleukin-il-17a/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/discovery-and-characterization-of-jnj-61178104-a-bispecific-antibody-against-human-tumor-necrosis-factor-tnf-alpha-and-interleukin-il-17a/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology